Sun Pharma Advanced Research shares plunged 15% to ₹166 following a mid-stage study failure of its psoriasis drug, marking the steepest decline since March 2020. The stock is down 16% year-to-date amid investor concerns over the setback.

• Psoriasis drug missed primary endpoint in mid-stage trial.
• Shares hit their worst drop since March 2020.
• Stock down 16% year-to-date.